Lasmiditan: Its Development and Potential Use.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 292, doi. 10.1002/cpdd.781
- By:
- Publication type:
- Article
Works matching IS 2160763X AND DT 2020 AND VI 9 AND IP 3
Results: 14
1
2
Single‐ and Multiple‐Dose Safety, Tolerability, and Pharmacokinetic Profiles of ASP8062: Results From 2 Phase 1 Studies.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 297, doi. 10.1002/cpdd.766
- By:
- Publication type:
- Article
3
Preemptive Anti–Stress Response Effects of Oxycodone Versus Sufentanil for Patients Undergoing Cardiac Valve Replacement—A Randomized Controlled Trial.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 321, doi. 10.1002/cpdd.764
- By:
- Publication type:
- Article
4
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 395, doi. 10.1002/cpdd.762
- By:
- Publication type:
- Article
5
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 411, doi. 10.1002/cpdd.756
- By:
- Publication type:
- Article
6
A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 307, doi. 10.1002/cpdd.749
- By:
- Publication type:
- Article
7
Bioequivalence Study of 2 Formulations of Rivaroxaban, a Narrow‐Therapeutic‐Index Drug, in Healthy Chinese Subjects Under Fasting and Fed Conditions.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 346, doi. 10.1002/cpdd.742
- By:
- Publication type:
- Article
8
A 3‐Part Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DSP‐6952 in Healthy Japanese Subjects and Those With ≤3 Spontaneous Bowel Movements per Week.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 353, doi. 10.1002/cpdd.731
- By:
- Publication type:
- Article
9
Assessment of Bezlotoxumab Immunogenicity.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 330, doi. 10.1002/cpdd.729
- By:
- Publication type:
- Article
10
Pharmacokinetic and Safety Profiles of a Fixed‐Dose Combination of Amlodipine, Valsartan, and Atorvastatin: A 3‐Period Replicate Crossover Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 386, doi. 10.1002/cpdd.727
- By:
- Publication type:
- Article
11
The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 375, doi. 10.1002/cpdd.726
- By:
- Publication type:
- Article
12
Pharmacokinetics and Bioequivalence Studies of Teriflunomide in Healthy Iranian Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 341, doi. 10.1002/cpdd.725
- By:
- Publication type:
- Article
13
A First‐in‐Human Phase 1 Randomized Single and Multiple Ascending Dose Study of RPh201 in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 366, doi. 10.1002/cpdd.720
- By:
- Publication type:
- Article
14
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 287, doi. 10.1002/cpdd.677
- Publication type:
- Article